EN DE

Sea Mild Biotechnology Co (7516) Fair Value & Analysis

Consumer Defensive · TW · Market cap 168M TWD

SM Sea Mild Biotechnology Co 7516 · TWO
Price8.90 TWD
Fair Value7.78 TWD
Upside-12.6%
Quality40/100
Watch Sea Mild Biotechnology Co for free, get notified when fair value or trend changes. Watch for free
Expensive Growth
Thin margins · 2.6% net margin
Low debt · negative free cash flow
Trails peers (4/12)
Narrow moat 29/100
Evidence: High Range 5.84 TWD – 9.73 TWD Share as image

Fair value as of: Jul 23, 2026

From 15 valuation models · updated 18 days ago

Share price +1.7% over the past month.

Below-average quality, and screening another 13% overvalued on our models.

What matters now

  • Our model range runs from 5.84 TWD (bear) to 9.73 TWD (bull), base 7.78 TWD. The closer the price sits to the lower half, the larger the margin of safety.
  • Quality 40/100 (below-average quality) with high evidence: the data supports the verdict.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (5 years)

24.30 TWD 3.43 TWD Fair Value 7.78 TWD Feb 2021 Aug 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 23, 2026.

How to read this chart

60‑month range 3.43 TWD – 24.30 TWD · fair‑value band 5.84 TWD – 9.73 TWD · the 8.90 TWD price screens above the 7.78 TWD fair value. Dashed = 300-day average. As of Jul 23, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Sea Mild Biotechnology Co (7516) currently trades at 8.90 TWD, while our model-based Fair Value estimate is 7.78 TWD, implying the stock looks roughly 12.6% overvalued today. The Quality Score stands at 40/100 (below-average quality), in the Consumer Defensive sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).

Over the trailing twelve months, Sea Mild Biotechnology Co generated revenue of 342M TWD at a net margin of 2.6%. Revenue declined 3.6% year over year. It earns a return on equity of 8.3%. The balance sheet holds a net cash position of 13.0M TWD. Fundamentals as of Jul 23, 2026

Our scenario range runs from 5.84 TWD (bear case) to 9.73 TWD (bull case); at 8.90 TWD, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 39% below its 52-week high and 4% above its 52-week low, currently below its 200-day average. For context, the median of 10 Consumer Defensive peers we cover trades at -26% fair-value upside, at -13%, 7516 screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Model Bear Bear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull Bull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
ROIC Compounder 6.43 TWD 7.07 TWD 7.88 TWD 72
Growth-Adj P/E 6.74 TWD 9.63 TWD 12.52 TWD 68
P/E Multiple 6.87 TWD 9.15 TWD 11.44 TWD 63
All 15 models by family
DCF Models
Owner Earnings 12.77 TWD 19.11 TWD 28.92 TWD 31
Earnings-Based
Graham-Dodd 3.11 TWD 17.07 TWD 23.68 TWD 54
Lynch FV 4.75 TWD 6.78 TWD 8.82 TWD 50
PEG = 1.0 4.75 TWD 6.78 TWD 8.82 TWD 46
EPV 6.24 TWD 6.52 TWD 6.74 TWD 59
Multiples
P/E Multiple 6.87 TWD 9.15 TWD 11.44 TWD 63
P/S Multiple 5.84 TWD 7.78 TWD 9.73 TWD 58
P/B Multiple 5.84 TWD 7.78 TWD 9.73 TWD 55
EV/EBIT 8.97 TWD 10.65 TWD 12.33 TWD 53
EV/EBITDA 19.38 TWD 24.53 TWD 29.69 TWD 54
EV/Revenue 7.32 TWD 8.78 TWD 10.24 TWD 43
Asset-Based
NCAV (Graham) 2.86 TWD 3.84 TWD 5.73 TWD 50
Economic Profit
Residual Income 4.28 TWD 4.40 TWD 4.37 TWD 61
ROIC Compounder 6.43 TWD 7.07 TWD 7.88 TWD 72
Growth Earnings
Growth-Adj P/E 6.74 TWD 9.63 TWD 12.52 TWD 68

Widest divergence: DCF Models (19.11 TWD) versus Asset-Based (3.84 TWD). Highest evidence: ROIC Compounder (72).

Notify me when 7516 reaches fair value

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.

Key figures & financial health

Revenue (TTM) 342M TWD
Revenue growth (YoY) -3.6%
Net margin 2.6%
Return on equity 8.3%
Free cash flow −7.4M TWD FY2025
P/E ratio 19.8
More key figures
Operating margin 1.2%
EPS (TTM) 0.4600 TWD
EPS growth (YoY) -77.8%
Net cash 13.0M TWD FY2024

Figures from reported company fundamentals · as of Jul 23, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 40/100

Of which business quality 41 · Market factors (momentum, volatility) 35

Profitability 44
Margins and returns on capital today
Quality Growth 33
Are margins and returns improving?
Cashflow 14
Earnings quality: real cash, not paper profit
Fin. Strength 51
Balance sheet, leverage, solvency risk
Investment 29
Disciplined investing over empire-building
Low Volatility 57
Calm price path (market factor)
Momentum 32
Price trend over the last 3–12 months (market factor)
52W Momentum 15
Distance to the 52-week high (market factor)
Net Issuance 82
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

About the company

Sea Mild Biotechnology Co., Ltd. manufactures and sells paints, coatings, and detergents in Taiwan. It offers laundry, household, and personal detergent, as well as epidemic prevention products under the Sea Mild Biotech brand name. The company was established in 2007 is headquartered in Taoyuan City, Taiwan.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Sea Mild Biotechnology Co reported revenue of 342M TWD in FY2025 versus 164M TWD in FY2021, a compound +20.2%/yr. Reported net income was 8.8M TWD in FY2025.

Growth Quality 50/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Latest Revenue (FY 2025)
342M TWD
Latest YoY
+7.2%
Avg. growth/yr (3Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+19.1%
Avg. growth/yr (5Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+10.5%
Avg. growth/yr (9Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+4.6%
Revenue +20.2%/yr
FY21 164M TWD
FY22 203M TWD
FY23 257M TWD
FY24 319M TWD
FY25 342M TWD
Net income
FY21 −52.1M TWD
FY22 −21.4M TWD
FY23 6.2M TWD
FY24 32.0M TWD
FY25 8.8M TWD

7516 screens 13% overvalued. Compare with The Procter & Gamble Company →

Share or link this analysis
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "Sea Mild Biotechnology Co Fair Value". https://www.fairvalue-calculator.com/stock/7516

Peer Group

Household & Personal Products · 244 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 40 · Bottom 25%
Fair Value upside −13% · Below median
Return on equity (TTM) 8% · Above median
Return on assets 2% · Below median
Net margin (TTM) 3% · Below median
Operating margin (TTM) 1% · Below median
Revenue growth -4% · Below median
Debt / equity 0.12× · Higher than median

Valuation Multiples vs Household & Personal Products median · lower = cheaper

P/E (TTM) 18.9× · Pricier than median
P/B 1.52× · Cheaper than median
P/S (TTM) 0.49× · Cheaper than median
EV/EBITDA 5.2× · Cheaper than 75% of peers

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 17 · sector 28
FUTURE 0 · sector 4
PAST 33 · sector 26
HEALTH 94 · sector 98
DIVIDEND 0 · sector 50

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Household & Personal Products stocks, each showing price versus our Fair Value estimate (as of Jul 23, 2026).

Stock Price Fair Value vs Fair Value
The Procter & Gamble Company PG $146.80 $108.16 -26%
Unilever PLC ULN 1,080 MXN 1,273 MXN +18%
Hindustan Unilever Limited HINDUNILVR ₹2,144 ₹1,000 -53%
Essity AB ESSITYA kr 279.00 kr 250.02 -10%
Godrej Consumer Products Limited GODREJCP ₹1,088 ₹367.64 -66%
Marico Limited MARICO ₹846.75 ₹233.05 -72%
APR Co 278470 375,000 KRW 151,222 KRW -60%
Dabur India Limited DABUR ₹429.45 ₹181.60 -58%
Kimberly-Clark de México, S. A. B. de C. V., KIMBERA 38.07 MXN 50.09 MXN +32%
PT Unilever Indonesia Tbk UNVR 1,730 IDR 1,934 IDR +12%

Compare Sea Mild Biotechnology Co with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Consumer Defensive stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Frequently asked questions

Is Sea Mild Biotechnology Co (7516) overvalued or undervalued?
As of Jul 23, 2026, our model estimates a fair value of 7.78 TWD versus a price of 8.90 TWD, about −13% (overvalued).
What is the fair value of 7516?
Our model-based fair value for Sea Mild Biotechnology Co is 7.78 TWD (as of Jul 23, 2026), built from audited fundamentals. The current price is 8.90 TWD.
What is the quality score of 7516?
Sea Mild Biotechnology Co has a Quality Score of 40/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of Sea Mild Biotechnology Co (7516)?
Sea Mild Biotechnology Co reported trailing-twelve-month revenue of about 342M TWD (latest available figure, as of Jul 23, 2026).
What is the net profit margin of 7516?
The net profit margin of Sea Mild Biotechnology Co is about 2.6%, meaning it keeps roughly 2.6% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Track Sea Mild Biotechnology Co and try Pro for 14 days

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.